TLX Telix Pharmaceuticals Limited
Company Analysis
Latest News
Telix Bets $1.65 Billion on a Radioactive Drug Supplier — But Will Shareholders Pay the Price for an FDA-Rejected Asset?
Shares plunged 11% to $11.21 as Telix Pharmaceuticals unveiled its largest-ever deal: a US$1.65 billion acquisition of Germany's ITM Isotope Technologies...
🔴 Telix Pharmaceuticals is trading 11% down in pre-market after announcing US$1.65 billion acquisition of ITM
Telix Pharmaceuticals is trading 10.96% down now at $11.21 in pre-market after announcing a US$1.65 billion acquisition of ITM Isotope Technologies Munich on...
🔴 Telix Pharmaceuticals is trading 4.7% down in pre-market after announcing US$1.65 billion ITM acquisition
Telix Pharmaceuticals is trading 4.7% down now at $12.00 after announcing a strategic agreement to acquire ITM Isotope Technologies Munich for US$1.65...
🟢 Telix Pharmaceuticals is trading 8% up today as markets recover after Fed's September 16 decision
Telix Pharmaceuticals is trading 7.51% up now at $12.58 as U.S. equities recover following the Federal Reserve’s September 16 rate decision. - The S&P 500 and...
🟢 Telix Pharmaceuticals is trading 5.49% up in pre-market as Nasdaq and S&P 500 rebound
Telix Pharmaceuticals is trading 5.49% up in pre-market at $12.48 after a broader pre-market recovery lifted major U.S. indexes. - Nasdaq Composite rose...
🔴 Telix Pharmaceuticals is trading 7.13% down today on profit-taking after Pixclara FDA approval
Telix Pharmaceuticals is trading 7.13% down at $11.91, apparently reflecting profit-taking after the September 14 FDA approval of Pixclara. - Shares rose...
🔴 Telix Pharmaceuticals is trading 4.1% down in pre-market — possible profit-taking after Pixclara approval
Telix Pharmaceuticals is trading 4.13% down at $12.30 in pre-market, possibly reflecting profit-taking after its approval-driven rally. - It rose 8.91% to...
🟢 Telix Pharmaceuticals is trading 10.03% up today after FDA approval of Pixclara for glioma imaging
Telix Pharmaceuticals is trading 10.03% up now at $12.96 after the U.S. FDA approved Pixclara on September 14, 2026, for glioma imaging. - Pixclara is the...
🟢 Telix Pharmaceuticals is trading 8.32% up today after FDA approval of Pixclara for glioma imaging
Telix Pharmaceuticals is trading 8.32% up at $12.76 after the U.S. FDA approved Pixclara on September 14, 2026, for glioma imaging. - Pixclara is the first...
🟢 Telix Pharmaceuticals is trading 4.16% up today after FDA approves Pixclara for glioma imaging
Telix Pharmaceuticals is trading 4.16% up at $11.73 after the FDA approved Pixclara for imaging gliomas. - Pixclara is the first FDA-approved FET-PET imaging...
Telix Wins Its First Brain-Cancer Drug Approval — But Can a Niche Imaging Product Move the Needle for a Billion-Dollar Business?
Shares jumped 7.2% to $12.10 as Telix Pharmaceuticals landed the first-ever FDA-approved imaging drug for brain cancer, handing the Australian...
🟢 Telix Pharmaceuticals is trading 7% up in pre-market after FDA approval of Pixclara for glioma imaging
Telix Pharmaceuticals is trading 7.17% up in pre-market at $12.10 after U.S. FDA approval of Pixclara. - Pixclara is indicated for PET imaging to...
🟢 Telix Pharmaceuticals is trading 6.54% up in after-hours trading as Pixclara’s PDUFA outcome remains unconfirmed
Telix Pharmaceuticals is trading 6.54% up at $12.03 in after-hours trading, supported by broader U.S. indexes gaining more than 0.5%. - It closed at $11.29 on...
🔴 Telix Pharmaceuticals is trading 4.37% down today despite broad U.S. market gains
Telix Pharmaceuticals is trading 4.37% down at $11.38 on September 11, 2026, despite broad U.S. market gains; the precise catalyst remains unclear. - The key...
🟢 Telix Pharmaceuticals is trading 4.17% up today ahead of FDA’s September 11 Pixclara decision
Telix Pharmaceuticals is trading 4.17% up at $12.48 as investors focus on the FDA’s September 11 decision deadline for Pixclara, its brain-cancer imaging...
Telix Rises 5%, Awaiting FDA Decision on Brain Cancer Imaging Agent
Telix Pharmaceuticals shares rose approximately 5% this week. The U.S. Food and Drug Administration (FDA) is expected to announce a decision on the Pixclara...
🟢 Telix Pharmaceuticals is trading 4.72% up in pre-market after completing 350-patient BiPASS enrollment
Telix Pharmaceuticals is trading at $11.99, +4.72% in pre-market after completing enrollment of 350 patients in its Phase 3 BiPASS study. • The company...
Telix Fills Its Prostate Cancer Trial and Gets an FDA Nod — But Can It Turn Imaging Into a Billion-Dollar Franchise?
Shares jumped +6.5% to $11.56 as Telix Pharmaceuticals announced it completed enrollment of 350 patients in its Phase 3 BiPASS study — a late-stage trial...
🟢 Telix Pharmaceuticals is trading 6.5% up today after completing 350-patient Phase 3 BiPASS enrollment
Telix Pharmaceuticals is trading at $11.56, up +6.54% on September 2, 2026, after completing enrollment of 350 patients in the Phase 3 BiPASS study. - Aligned...
🟢 Telix Pharmaceuticals is trading 5% up in pre-market after completing Phase 3 BiPASS enrollment
Telix Pharmaceuticals is trading 5.25% up at $11.42 after announcing completion of patient enrollment in the Phase 3 BiPASS study and alignment with the FDA on...